—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Almirall S.A. (ALM.MC) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ALM.MC, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 56/100 · S&P 500 fund at 61, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-15
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 85th percentile of the window, -2.5% over 20 sessions. Factor regime → 2026-10-15
  • Sovereign pressure Index -0.32 · down 0.76 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-14
Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ALM.MC on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Almirall S.A.

ALM.MC in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Almirall develops medicines for skin conditions such as psoriasis, atopic dermatitis, acne and actinic keratosis, alongside products in several other therapeutic areas. It runs a pipeline of experimental compounds at different trial stages, often working with outside research partners on early-stage science. The company is headquartered in Barcelona, Spain, and trades on the Madrid exchange.
Where it sits in the stack
Almirall carries no seat in our index; it sits in the specialty pharmaceutical sleeve of our universe, outside the AI build-out stack the diary otherwise tracks.
Who it is priced against
The wider market groups it with other skin-focused biopharmaceutical firms; a name often mentioned alongside it is Galderma.
Why Closelooknet tracks it
Almirall holds no seat in our index and carries no Closelooknet score; the diary has not yet built coverage for it.
What the diary watches
Whether the dermatology pipeline, including compounds still in early and mid-stage trials, advances and changes how the skin-health portfolio is read.

Almirall S.A. (ALM.MC) trades on the MC exchange in Spain.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 1.50%, annual · last 0.15 EUR on 2026-05-14

Dividends and capital return

What ALM.MC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.15 EUR per share · a 1.50% yield on the 2026-10-15 close 1 distribution, paid once a year 2026-10-15
  • Change on the year +1.7% against the prior twelve months prior twelve months 0.15 EUR per share
  • Last distribution 0.15 EUR per share as the price series records it, within days of the ex-date 2026-05-14
  • By calendar year 2025: 0.15 EUR (partial) · 2026: 0.15 EUR to date first distribution recorded in the three-year window: 2025-05-15

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-16

Quick answers

What is Almirall S.A. (ALM.MC)?

Almirall S.A. trades as ALM.MC on the MC exchange (Spain) in the Closelooknet research universe, as of the registry build of 2026-10-16.

Is ALM.MC in a Closelooknet index?

Not currently — Almirall S.A. is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-16.

Where does ALM.MC trade against its moving averages?

Downtrend stack: Trades -2.5% vs the 50-day and -12.3% vs the 200-day average, 26.7% below the 52-week high and +3.2% off the 52-week low. Computed from daily closes. As of 2026-10-15 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Almirall S.A. compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic), Almirall S.A. (ALM.MC) sits 26.7% below its 52-week high, 2.5% below its 50-day average; Laboratorios Farmaceuticos ROVI (ROVI.MC) is 32.4% below, Lantheus Holdings Inc (LNTH) is 10.6% below, Bausch Health Companies Inc (BHC.TO) is 19.0% below. Put any of them next to ALM.MC in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Almirall S.A. do?

Almirall develops medicines for skin conditions such as psoriasis, atopic dermatitis, acne and actinic keratosis, alongside products in several other therapeutic areas. It runs a pipeline of experimental compounds at different trial stages, often working with outside research partners on early-stage science. The company is headquartered in Barcelona, Spain, and trades on the Madrid exchange. The wider market groups it with other skin-focused biopharmaceutical firms; a name often mentioned alongside it is Galderma.

Where does Almirall S.A. sit in the AI build-out?

Almirall carries no seat in our index; it sits in the specialty pharmaceutical sleeve of our universe, outside the AI build-out stack the diary otherwise tracks. Almirall holds no seat in our index and carries no Closelooknet score; the diary has not yet built coverage for it.

Does Almirall S.A. pay a dividend?

Almirall S.A. has paid 0.15 EUR per share over the last twelve months, paid once a year, a trailing yield of 1.50% on the 2026-10-15 close; the last distribution recorded in the price series was 0.15 EUR on 2026-05-14. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ALM.MC, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.